Trial Profile
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 05 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 28 Jul 2023 Planned End Date changed from 1 Dec 2023 to 31 Dec 2023.
- 31 May 2023 Planned End Date changed from 9 Jun 2023 to 1 Dec 2023.